Lineage Cell Therapeutics, Inc. (LCTX) compared with its closest peers (STRO, AGEN, IKT, NMRA, AVXL). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Sutro Biopharma, Inc. (STRO) | $347.32M | -0.5 |
| Agenus Inc. (AGEN) | $336.68M | 2.4 |
| Inhibikase Therapeutics, Inc. (IKT) | $333.49M | -4.2 |
| Neumora Therapeutics, Inc. Common Stock (NMRA) | $304.39M | -1.2 |
| Anavex Life Sciences Corp. (AVXL) | $296.55M | -16.5 |
| SAB Biotherapeutics, Inc. (SABS) | $288.27M | -4.7 |
| Surrozen, Inc. (SRZN) | $278.18M | -0.7 |
| Fate Therapeutics, Inc. (FATE) | $277.98M | -0.9 |
| Alector, Inc. (ALEC) | $260.91M | -1.1 |
| Protara Therapeutics, Inc. (TARA) | $216.11M | -4.0 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
LCTX overview · LCTX earnings · LCTX financials · LCTX KPIs · LCTX investor relations · LCTX ownership · LCTX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.